UBS Group
NDRA icon

UBS Group’s ENDRA Life Sciences NDRA Stock Holding History

UBS Group’s Portfolio NDRA Stock Details NDRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$362 Sell
68
-84
-55% -$427 ﹤0.01% 9896
2026
Q1 		$707 Buy
152
+140
+1,167% +$555 ﹤0.01% 9780
2025
Q4 		$54 Sell
12
-94
-89% -$536 ﹤0.01% 10262
2025
Q3 		$570 Sell
106
-4,589
-98% -$24K ﹤0.01% 9620
2025
Q2 		$16.5K Buy
+4,695
New +$18.1K ﹤0.01% 8567
2025
Q1 		– Sell
-95
Closed -$595 – 10555
2024
Q4 		$595 Buy
+95
New +$633 ﹤0.01% 9416
2024
Q3 		– Sell
-32
Closed -$5.38K – 9878
2024
Q2 		$5.38K Buy
+32
New +$13.8K ﹤0.01% 8003
2024
Q1 		– Hold
0
– – – 8867
2023
Q1 		– Sell
-1
Closed -$8.75K – 10092
2022
Q4 		$8.75K Buy
+1
New +$8.38K ﹤0.01% 8734
2022
Q3 		– Sell
-1
Closed -$9K – 10718
2022
Q2 		$9K Hold
1
– – ﹤0.01% 8155
2022
Q1 		$11K Hold
1
– – ﹤0.01% 8306
2021
Q4 		$19K Hold
1
– – ﹤0.01% 7907
2021
Q3 		$49K Hold
1
– – ﹤0.01% 6351
2021
Q2 		$64K Hold
1
– – ﹤0.01% 6213
2021
Q1 		$79K Buy
+1
New +$74.9K ﹤0.01% 6140
2020
Q4 		– Hold
0
– – – 7837
2020
Q3 		– Hold
0
– – – 7128
2020
Q2 		– Hold
0
– – – 7780
2020
Q1 		– Hold
0
– – – 7621
2019
Q2 		– Hold
0
– -$3K – 8052
2019
Q1 		– Hold
0
– – – 7341
2018
Q2 		– Hold
0
– -$6K – 8159
2018
Q1 		– Hold
0
– – – 7153
2017
Q4 		– Hold
0
– -$12K – 8002
2017
Q3 		– Hold
0
– – – 6787
2017
Q2 		– Hold
0
– – – 6917

Other funds holding NDRA

ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
CFG
Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return

UBS Group's NDRA Position: Q2 2026 in Review

UBS Group reduced its ENDRA Life Sciences (NDRA) stake by 55% in Q2 2026, selling an estimated $427 and leaving 68 shares worth $362. The position accounts for ﹤0.01% of the portfolio, ranked #9896.

UBS Group first reported a position in NDRA in Q1 2021 and has held it in 14 quarters since. The position peaked at $79K in Q1 2021. 10 funds tracked by Wall St. Rank hold NDRA as of Q2 2026.

  • UBS Group held 68 shares of ENDRA Life Sciences worth $362 as of Q2 2026.
  • UBS Group sold 84 ENDRA Life Sciences shares in Q2 2026, an estimated $427.
  • ENDRA Life Sciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9896 holding.
  • UBS Group first reported a position in ENDRA Life Sciences in Q1 2021 and has held it in 14 quarters since.
  • UBS Group's ENDRA Life Sciences position peaked at $79K in Q1 2021.
  • 10 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.